Progress New Assets (one Pre-new Molecular Entity And One First-time-in-human Start) For Tuberculosis That Act Synergistically With Bedaquiline, Cytochrome Bc Or Cytochrome Bd Inhibitors

  Address - Netherlands

  Contact details - 565656565

  Tender notice no. - 76454545

  MT Ref Id - 10352696

  Document Type - Tender Notices

Description - Grant agreement ID: 853903Start date 1 May 2019End date 30 April 2025Overall budget € 9 962 900 ObjectiveDespite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the worldâ €™s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Th

Mt Ref Id - 10352696

Deadline - Apr 30, 2025